RAPT Therapeutics Management
Management criteria checks 2/4
RAPT Therapeutics' CEO is Brian Wong, appointed in Aug 2015, has a tenure of 9.33 years. total yearly compensation is $6.59M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth $832.52K. The average tenure of the management team and the board of directors is 4.9 years and 7.6 years respectively.
Key information
Brian Wong
Chief executive officer
US$6.6m
Total compensation
| CEO salary percentage | 9.2% |
| CEO tenure | 9.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 4.9yrs |
| Board average tenure | 7.6yrs |
Recent management updates
Recent updates
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?
Nov 10
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$107m |
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$118m |
| Dec 31 2023 | US$7m | US$605k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$109m |
| Jun 30 2023 | n/a | n/a | -US$99m |
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$5m | US$580k | -US$84m |
| Sep 30 2022 | n/a | n/a | -US$79m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$3m | US$540k | -US$69m |
| Sep 30 2021 | n/a | n/a | -US$64m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$4m | US$500k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$47m |
| Dec 31 2019 | US$2m | US$447k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$425k | -US$36m |
Compensation vs Market: Brian's total compensation ($USD6.59M) is above average for companies of similar size in the US market ($USD646.54K).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian Wong (52 yo)
9.3yrs
Tenure
US$6,591,617
Compensation
Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$6.59m | 1.41% $ 832.5k | |
| CFO, Principal Accounting Officer & Secretary | 5yrs | US$2.18m | 0.034% $ 19.8k | |
| Chief Medical Officer | 9.6yrs | US$1.90m | 0.045% $ 26.6k | |
| Vice President of Technology | no data | no data | no data | |
| Chief Scientific Officer | 5.5yrs | US$1.48m | 0.074% $ 43.6k | |
| General Counsel | 1.9yrs | no data | no data | |
| Chief Human Resources Officer | 2.6yrs | no data | no data | |
| Senior Vice President of Quantitative & Computational Biology | 4.8yrs | no data | no data | |
| Senior Vice President of Drug Discovery & Preclinical Development | 5.9yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 2.3yrs | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data |
4.9yrs
Average Tenure
58yo
Average Age
Experienced Management: RAPT's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.3yrs | US$6.59m | 1.41% $ 832.5k | |
| Independent Chairman of the Board | 9.6yrs | US$300.28k | 0.27% $ 160.1k | |
| Independent Director | 5yrs | US$277.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.6yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Independent Director | 6.9yrs | US$267.78k | 0% $ 0 | |
| Independent Director | 8yrs | US$260.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.6yrs
Average Tenure
65yo
Average Age
Experienced Board: RAPT's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 15:58 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RAPT Therapeutics, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leon Wang | Barclays |
| Gao Yi Chen | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |